Merck & Co. (MRK) Q4 2025 (USD): adj. EPS 2.04 (exp. 2.01), Revenue 16.4bln (exp. 16.20bln)
Importance
Level 1
KEY PHARMA SALES:
- Q4 Keytruda Sales USD 8.37bln (exp. 8.31bln)
- Q4 Gardasil Sales USD 1.03bln (exp. 0.991bln)
- Q4 Winrevair Sales USD 467mln
GUIDANCE:
- FY EPS view 5.00-5.15 (exp. 5.27)
- FY Rev. view USD 65.5-67.0bln (exp. 67.4bln)
#UNITED STATES#USD#EUR#GERMANY#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#MERCK & CO INC#MRK.US#MERCK KGAA#IMPORTANT#FOREX#EQUITIES#METALS#EU SESSION#PHARMACEUTICALS#METALS & MINING#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DAX 40 INDEX#MRK#DXY#TRADE#US EQUITIES